Two Sigma Advisers Reduces $13M in Alphatec Holdings, Inc. ($ATEC)
Key Points
- Two Sigma Advisers changed its Alphatec Holdings, Inc. ($ATEC) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ATEC is Strong Buy and an average price target of $16.73.
- $ATEC last traded around $8.13.
Two Sigma Advisers reduced its position in Alphatec Holdings, Inc. ($ATEC), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Alphatec Holdings, Inc. after selling 1,635,100 shares during the quarter.
Alphatec Holdings, Inc. ($ATEC) Stock
Alphatec Holdings, Inc. Earnings
Analysts Set New Price Targets
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.